{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:28:52Z","timestamp":1789730932428,"version":"4.0.1"},"reference-count":33,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T00:00:00Z","timestamp":1731283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100002424","name":"Fujifilm Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002424","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Clin Biochem"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Reports have shown that the kynurenine pathway, one of the pathways by which tryptophan is metabolized, is activated in patients with diffuse large B-cell lymphoma (DLBCL). Activation of the kynurenine pathway triggers the production of various metabolites, such as kynurenine (Kyn), 3-hydroxykynurenine (3-HK), 3-hydroxyanthranilic acid (3-HAA), kynurenic acid (KA), and anthranilic acid (AA), which contribute to immune tolerance. The current study aimed to investigate the changes in metabolites of kynurenine pathway in DLBCL patients and evaluate their performance predicting DLBCL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Changes in metabolites of kynurenine pathway were examined using high-performance liquid chromatography in 35 DLBCL patients (age 61.2 \u00b1 13.5\u00a0years) and 44 healthy controls (age 58.5 \u00b1 12.5\u00a0years).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>DLBCL patients had significantly higher levels of 3-HK, AA, and 3-HAA but lower levels of tryptophan (Trp) and KA compared to healthy controls. Given that the ratio of each metabolite represents the change in the Kyn pathway, the 3-HK\/KA ratio was examined. Notably, DLBCL patients had a significantly higher 3-HK\/KA ratio compared to healthy controls. In DLBCL, the area under the receiver operative characteristic (ROC) curve for 3-HK\/KA (0.999) was higher than that for lactate dehydrogenase (0.885) and comparable to that for soluble interleukin-2 receptor (sIL-2R) (0.997). Based on ROC curve analysis, the 3-HK\/KA ratio was found to be useful biomarker for the diagnosis of DLBCL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our results suggest that the 3-HK\/KA ratio is a clinically useful biomarker of DLBCL. Moreover, its combination with existing markers, such as sIL-2R, can improve its effectiveness of diagnosing DLBCL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/00045632241297873","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T01:45:51Z","timestamp":1729647951000},"page":"109-117","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Usefulness of the 3-hydroxykynurenine\/kynurenic acid ratio as a diagnostic biomarker for diffuse larger B-cell lymphoma"],"prefix":"10.1177","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8825-9188","authenticated-orcid":false,"given":"Yasuko","family":"Yamamoto","sequence":"first","affiliation":[{"name":"Advanced Diagnostic System Development, Fujita Health University Graduate School of Health Sciences, Toyoake, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoe","family":"Goto","sequence":"additional","affiliation":[{"name":"Department of Hematology, Fujita Health University School of Medicine, Toyoake, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengo","family":"Kambara","sequence":"additional","affiliation":[{"name":"Medical Systems Research &amp; Development Center, Medical Systems Business Division, FUJIFILM Corporation, Amagasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suwako","family":"Fujigaki","sequence":"additional","affiliation":[{"name":"Advanced Diagnostic System Development, Fujita Health University Graduate School of Health Sciences, Toyoake, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9655-1074","authenticated-orcid":false,"given":"Hidetsugu","family":"Fujigaki","sequence":"additional","affiliation":[{"name":"Advanced Diagnostic System Development, Fujita Health University Graduate School of Health Sciences, Toyoake, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Takemura","sequence":"additional","affiliation":[{"name":"Advanced Diagnostic System Development, Fujita Health University Graduate School of Health Sciences, Toyoake, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshitaka","family":"Nabeshima","sequence":"additional","affiliation":[{"name":"Laboratory of Health and Medical Science Innovation, Fujita Health University, Toyoake, Japan"},{"name":"Japanese Drug Organization of Appropriate Use and Research, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Tomita","sequence":"additional","affiliation":[{"name":"Department of Hematology, Fujita Health University School of Medicine, Toyoake, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuniaki","family":"Saito","sequence":"additional","affiliation":[{"name":"Advanced Diagnostic System Development, Fujita Health University Graduate School of Health Sciences, Toyoake, Japan"},{"name":"Laboratory of Health and Medical Science Innovation, Fujita Health University, Toyoake, Japan"},{"name":"Japanese Drug Organization of Appropriate Use and Research, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,11,11]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1805"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26151"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.807271"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13432"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/prot.22819"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)99420-2"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.281.5380.1191"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27010273"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms221810134"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2013.02.001"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2009.01393.x"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.643472"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05021-2"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-58806-w"},{"issue":"3","key":"e_1_3_4_18_2","first-page":"189","article-title":"The utility of lactate dehydrogenase in the follow up of patients with diffuse large B-cell lymphoma","volume":"35","author":"William BM","year":"2013","unstructured":"William BM, Bongu NR, Bast M, et al. The utility of lactate dehydrogenase in the follow up of patients with diffuse large B-cell lymphoma. Rev Bras Hematol Hemoter 2013; 35(3): 189\u2013191.","journal-title":"Rev Bras Hematol Hemoter"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291402"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-010-1093-z"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.651687"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5903"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-019-03332-w"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00726-014-1790-3"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2009.06.015"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-510X(90)90198-V"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2021.13051"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2982.2009.01390.x"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2012.06.044"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m4087"},{"issue":"5","key":"e_1_3_4_31_2","first-page":"474","article-title":"Serum soluble interleukin-2 receptor levels for screening for malignant lymphomas and differential diagnosis from other conditions","volume":"11","author":"Murakami J","year":"2019","unstructured":"Murakami J, Arita K, Wada A, et al. Serum soluble interleukin-2 receptor levels for screening for malignant lymphomas and differential diagnosis from other conditions. Molecular and Clinical Oncology 2019; 11(5): 474\u2013482.","journal-title":"Molecular and Clinical Oncology"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-44123-5"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.3399\/bjgp19X701009"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1186\/2052-1839-13-9"}],"container-title":["Annals of Clinical Biochemistry: International Journal of Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/00045632241297873","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/00045632241297873","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/00045632241297873","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:25:32Z","timestamp":1777379132000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/00045632241297873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,11]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1177\/00045632241297873"],"URL":"https:\/\/doi.org\/10.1177\/00045632241297873","relation":{},"ISSN":["0004-5632","1758-1001"],"issn-type":[{"value":"0004-5632","type":"print"},{"value":"1758-1001","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,11]]}}}